Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRISPR pooled screen and QuantSeq 3' mRNA sequencing to identify microRNAs (miRNAs) important for Breast Cancer 3D growth [CRISPR screen]

ABSTRACT: Breast cancer (BC) is a heterogeneous malignancy with distinct molecular subtypes and clinical characteristics. Tumor-initiating cells (TICs) constitute a small subset of cancer cells responsible for tumor initiation and progression. MicroRNAs (miRNAs), small non-coding RNA molecules, play a pivotal role in regulating gene expression and have been implicated in cancer development and progression. In this study, we conducted genome-wide CRISPR-Cas9 screens within 3D tumorspheres of two BC cell lines, MCF7 (ER+) and HCC1395 (TNBC). Our objective was to identify miRNAs that govern TIC viability, employing CRISPR/Cas9 pooled screens that targeted a total of 19,052 genes and 1,864 miRNAs. By suppressing relevant miRNAs following QuantSeq 3' mRNA sequencing we identify the genes regulated by those miRNAs

ORGANISM(S): Homo sapiens

PROVIDER: GSE243882 | GEO | 2024/03/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CRISPR pooled screen and QuantSeq 3' mRNA sequencing to identify microRNAs (miRNAs) important for Breast Cancer 3D growth [RNA-seq]

Project description:Breast cancer (BC) is a heterogeneous malignancy with distinct molecular subtypes and clinical characteristics. Tumor-initiating cells (TICs) constitute a small subset of cancer cells responsible for tumor initiation and progression. MicroRNAs (miRNAs), small non-coding RNA molecules, play a pivotal role in regulating gene expression and have been implicated in cancer development and progression. In this study, we conducted genome-wide CRISPR-Cas9 screens within 3D tumorspheres of two BC cell lines, MCF7 (ER+) and HCC1395 (TNBC). Our objective was to identify miRNAs that govern TIC viability, employing CRISPR/Cas9 pooled screens that targeted a total of 19,052 genes and 1,864 miRNAs. By suppressing relevant miRNAs following QuantSeq 3' mRNA sequencing we identify the genes regulated by those miRNAs

2024-03-31 | GSE243883 | GEO

CRISPR screen pilot

Project description:This project carries out the pilot CRISPR/Cas9 screens in the K562 background. Its goals are to confirm that positive controls work, and to assess the effects of experimental parameters (listed below) on the sequencing-based fitness readout. We test 1) length of selection 2) biological replicates 3) sampling variation during bottlenecks 4) sampling variation during DNA preparation 5) sequencing depth to inform the setup for the next round of experiments. To do so, we propose to sequence 13 samples (6 timepoints, 2 biological replicates, 2 severe bottlenecks during growth, 2 bottlenecks during DNA preparation, and the screening library itself) on two lanes of HiSeq, using 19bp reads. The sequencing libraries are prepared in our lab.This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

2016-05-03 | E-ERAD-459 | biostudies-arrayexpress

Glioblastoma CRISPR Screen

Project description:This is an in vitro genome-wide CRISPR/cas9 screen in human glioblastoma stem cells, screening for genes essential for survival of these cells. These cells express cas9 and have been transfected with a guide RNA library causing gene knockouts. We will analyse the sequencing data for depletion of guide RNAs.

| EGAS00001001519 | EGA

Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibition [CRISPR mini screen]

Project description:CRISPR/Cas9 screens identified unexpected hits in human AML cell lines whose loss of function causes resistance to SHP2 inhibition

2023-02-20 | GSE218489 | GEO

Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibition [CRISPR genomic screen]

Project description:CRISPR/Cas9 screens identified unexpected hits in human AML cell lines whose loss of function causes resistance to SHP2 inhibition

2023-02-20 | GSE218488 | GEO

CRISPR-Cas9 Whole-Genome Screen Identify Critical Genes Regulating Cholesterol Metabolism in Macrophages

Project description:We designed CRISPR-Cas9 whole genome screens to identify and rank critical genes for cholesterol metabolism in modified LDL treated BMDMs

2024-11-01 | GSE190474 | GEO

Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ARID1A deficiency Hepatocellular Carcinoma

Project description:To uncover therapeutic strategies for ARID1A deficient HCC, we performed genome-scale CRISPR–Cas9 based synthetic lethality screens using ARID1A deficiency HCC cellular model

2023-09-11 | GSE228177 | GEO

Genome-wide CRISPR screen for regulators of SARS-CoV-2 programmed ribosomal frameshifting

Project description:Genome-wide CRISPR-Cas9 knockout screens were performed in dual-fluorescent frameshifting reporter cell lines to identify human host factors for SARS-CoV-2 programmed ribosomal frameshfiting.

2022-12-22 | GSE206101 | GEO

CRISPR-Cas9 RBM10 synthetic lethality screen

Project description:Genome-wide CRISPR-Cas9 knockout screen using TKOv1 sgRNA library was performed in isogenic RBM10-proficient and RBM10-deficient HCC827 cells.

2023-03-04 | E-MTAB-12724 | biostudies-arrayexpress

Genome wide CRISPR screen for Trametinib sensitivity in resistant MOLM13 cells using Y. Kosuke library

Project description:Cas9-expressing trametinib resistant MOLM-13 cell lines (TM1) were generated using the Cas9-Blst (Addgene, #52962) and expanded for genome-wide loss-of-function screens using the Y. Kosuke library (Addgene, #67989) Following transduction, cells cultured in the presence of trametinib (100 nM) or DMSO after lentiviral infection.

2024-02-22 | GSE235183 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data